CA2234824A1 - Treatment of traumatic brain injury - Google Patents

Treatment of traumatic brain injury Download PDF

Info

Publication number
CA2234824A1
CA2234824A1 CA002234824A CA2234824A CA2234824A1 CA 2234824 A1 CA2234824 A1 CA 2234824A1 CA 002234824 A CA002234824 A CA 002234824A CA 2234824 A CA2234824 A CA 2234824A CA 2234824 A1 CA2234824 A1 CA 2234824A1
Authority
CA
Canada
Prior art keywords
treatment
ethyl
tetrazol
traumatic brain
brain injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002234824A
Other languages
English (en)
French (fr)
Inventor
Brian R. Pike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2234824A1 publication Critical patent/CA2234824A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002234824A 1995-11-06 1996-11-05 Treatment of traumatic brain injury Abandoned CA2234824A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
DK1232/95 1995-11-06

Publications (1)

Publication Number Publication Date
CA2234824A1 true CA2234824A1 (en) 1997-05-15

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002234824A Abandoned CA2234824A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Country Status (18)

Country Link
EP (1) EP0866706A1 (is)
JP (1) JPH11514654A (is)
KR (1) KR19990067353A (is)
AU (1) AU706594B2 (is)
BG (1) BG63150B1 (is)
BR (1) BR9611396A (is)
CA (1) CA2234824A1 (is)
CZ (1) CZ287441B6 (is)
EA (1) EA000531B1 (is)
HU (1) HUP9901051A2 (is)
IS (1) IS4726A (is)
NO (1) NO982036L (is)
NZ (1) NZ321546A (is)
PL (1) PL326490A1 (is)
SK (1) SK58198A3 (is)
TR (1) TR199800801T2 (is)
WO (1) WO1997017074A1 (is)
ZA (1) ZA969320B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
BG102480A (en) 1999-01-29
EP0866706A1 (en) 1998-09-30
PL326490A1 (en) 1998-09-28
BR9611396A (pt) 1999-07-13
AU7490096A (en) 1997-05-29
EA000531B1 (ru) 1999-10-28
EA199800434A1 (ru) 1998-10-29
NO982036D0 (no) 1998-05-05
JPH11514654A (ja) 1999-12-14
CZ138998A3 (cs) 1998-10-14
AU706594B2 (en) 1999-06-17
IS4726A (is) 1998-04-27
NZ321546A (en) 2000-12-22
MX9803432A (es) 1998-09-30
TR199800801T2 (xx) 1998-08-21
NO982036L (no) 1998-06-25
SK58198A3 (en) 1998-10-07
WO1997017074A1 (en) 1997-05-15
CZ287441B6 (en) 2000-11-15
KR19990067353A (ko) 1999-08-16
ZA969320B (en) 1997-05-30
BG63150B1 (bg) 2001-05-31
HUP9901051A2 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
DE60211937T2 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
WO1994002150A1 (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
EP0615751B1 (en) Use of tachykinin antagonists in the treatment of emesis
JPH10508866A (ja) オンダンセトロンを含有する経口組成物
US5290783A (en) Use of spiperone derivatives as immunosuppressant agents
US6297262B1 (en) Treatment of schizophrenia and psychosis
US4835173A (en) Method of medical treatment
AU706594B2 (en) Treatment of traumatic brain injury
EP0275668B1 (en) Use of ketone derivatives in the treatment of cognitive disorders
KR950010148B1 (ko) 중독증 치료용 의약품
AU764304B2 (en) Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders
US20060135507A1 (en) Therapeutic agent for overactive bladder involved in aging
US20060269598A1 (en) Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use
JP2005532274A (ja) 雄避妊のための非ホルモン的アプローチ
US20060269597A1 (en) Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions
EP0690715B1 (en) Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses
CA2022379A1 (en) Medicaments
MXPA98003432A (en) Treatment of traumat cerebral damage
US20030166667A1 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
JPH01250319A (ja) 医薬

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued